Market closedADR

Genmab/GMAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Genmab

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Ticker

GMAB
Trading on

Industry

Biotechnology

Headquarters

Copenhagen, Denmark

Employees

2,526

Genmab Metrics

BasicAdvanced
$15B
Market cap
1.90
P/E ratio
$12.38
EPS
0.84
Beta
-
Dividend rate
$15B
0.84
$33.60
$23.24
647K
5.027
5.019
2.987
3.29
176.94%
10.97%
18.55%
1.901
0.549
3.29
6.19
1.604
17.19%
19.99%
37.46%
30.42%

What the Analysts think about Genmab

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Genmab stock.

Genmab Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Genmab Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy GMAB

$

Sign up or log in to buy
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Genmab stock?

Genmab (GMAB) has a market cap of $15B as of October 13, 2024.

What is the P/E ratio for Genmab stock?

The price to earnings (P/E) ratio for Genmab (GMAB) stock is 1.9 as of October 13, 2024.

Does Genmab stock pay dividends?

No, Genmab (GMAB) stock does not pay dividends to its shareholders as of October 13, 2024.

When is the next Genmab dividend payment date?

Genmab (GMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Genmab?

Genmab (GMAB) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.